Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTORPHANOL TARTRATE vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Management of moderate to severe pain,Preoperative medication,Supplement to balanced anesthesia,Relief of pain during labor,Off-label: Migraine headache (via intranasal route)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Butorphanol is extensively metabolized in the liver via hydroxylation and N-dealkylation, primarily by CYP3A4. The major metabolite is hydroxybutorphanol, which has some analgesic activity but is less potent.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 80% bound to plasma proteins (mainly alpha-1-acid glycoprotein and albumin).
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Vd: 4-5 L/kg (range 3-6 L/kg), indicating extensive tissue distribution, including CNS.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Intranasal: 60-70% (range 48-80%); IM: 80-100% (complete but variable); Oral: very low (<5%) due to extensive first-pass metabolism; not used orally.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No specific guidelines for dose adjustment in renal impairment; use with caution. For severe renal impairment (e GFR <30 m L/min), consider reducing dose and/or extending dosing interval due to potential accumulation of active metabolites.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50% and monitor for excessive sedation. Class C: Avoid use or reduce dose to 25% of normal and monitor closely.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Weight-based: 0.01-0.02 mg/kg intravenously or intramuscularly every 3-4 hours as needed; maximum single dose 1 mg. For intranasal: 1 mg as a single dose in patients ≥18 kg (for migraine). Not recommended for PCA in children.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Reduce initial dose by 50% (e.g., 0.5-1 mg IV/IM every 4-6 hours); titrate cautiously due to increased sensitivity to opioid effects and risk of respiratory depression. For intranasal, consider lower dose (0.5 mg). Monitor renal function.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Concomitant use of opioids with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Respiratory depression: especially in patients with compromised respiratory function or when used with other CNS depressants,Dependence and abuse liability: Schedule IV controlled substance,Increases in intracranial pressure: may exacerbate in patients with head injury,Cardiovascular effects: may increase cardiac workload and should be avoided in acute MI,Biliary tract spasm: may cause spasm of the sphincter of Oddi,Withdrawal: may precipitate withdrawal in opioid-dependent patients if given shortly after other mu-agonists
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to butorphanol tartrate or any component of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Known or suspected gastrointestinal obstruction,Patients who are physically dependent on mu-agonists due to risk of acute withdrawal
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid alcohol and grapefruit juice (may increase butorphanol levels). No specific food restrictions.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis produced increased fetal resorptions and decreased fetal weights at doses 3-6 times the human therapeutic dose. In the first trimester, risks cannot be ruled out. In the second and third trimesters, prolonged use may cause neonatal opioid withdrawal syndrome. Use near term may cause respiratory depression in the neonate.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Butorphanol is excreted into human milk. The milk-to-plasma ratio (M/P) is approximately 0.7. Limited data suggest low levels; however, due to potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends avoiding use while breastfeeding.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Pregnancy may alter butorphanol pharmacokinetics due to increased plasma volume and enhanced clearance. However, specific dose adjustment recommendations are not established. Use lowest effective dose for shortest duration. For labor analgesia, standard IV/IM doses (1-2 mg) may be used, but monitor for maternal and neonatal respiratory depression.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Butorphanol is a mixed agonist-antagonist opioid; may precipitate withdrawal in opioid-dependent patients. Ceiling effect on respiratory depression. Higher risk of psychotomimetic effects (dysphoria, hallucinations) compared to morphine. Onset: 1-2 min IV, 5-10 min IM; duration 3-4 hours. Nasal spray has bioavailability ~70%.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
May cause drowsiness or dizziness; avoid driving or operating machinery.,Do not take with alcohol or other CNS depressants.,Can cause nausea, vomiting, or sweating; report severe reactions.,Use exactly as prescribed; risk of dependence with long-term use.,If you are dependent on opioids, this drug may cause withdrawal symptoms.,Notify your doctor if you have a history of head injury, asthma, or liver/kidney disease.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Butorphanol, a mixed agonist-antagonist opioid, and dimenhydrinate, a histamine H1 antagonist, exhibit additive central nervous system (CNS) depression. Concurrent use increases the risk of profound sedation, respiratory depression, dizziness, and psychomotor impairment. These effects are dose-dependent and can lead to hazardous outcomes such as falls, respiratory compromise, or coma, particularly in elderly or debilitated patients."
"Concomitant use of butorphanol, a mixed agonist-antagonist opioid, with pipotiazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression, including sedation, respiratory depression, and hypotension. Pipotiazine may also potentiate the analgesic effects of butorphanol through antagonism at dopamine D2 receptors, but this combination increases the risk of extrapyramidal symptoms and neuroleptic malignant syndrome. Clinically, patients may experience excessive sedation, confusion, orthostatic hypotension, and impaired psychomotor function."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTORPHANOL TARTRATE vs ALFENTA, answered by our medical review team.
BUTORPHANOL TARTRATE is a Opioid Analgesic that works by Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTORPHANOL TARTRATE and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTORPHANOL TARTRATE is: 1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTORPHANOL TARTRATE and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTORPHANOL TARTRATE is classified as Category C. Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.